Welcome to LookChem.com Sign In|Join Free
  • or
Triethylene glycol monobenzyl ether, also known as Benzyl-PEG4-alcohol, is a PEG (polyethylene glycol) linker with an acid-labile benzyl protecting group and a reactive primary alcohol. The primary alcohol allows for further derivatization of the compound, while the hydrophilic PEG linker enhances its water solubility in aqueous media.

55489-58-2

Post Buying Request

55489-58-2 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

55489-58-2 Usage

Uses

Used in Biosensor Applications:
Triethylene glycol monobenzyl ether is used as a component in the preparation of self-assembled monolayers with multiple binding sites and biocompatible imprinted cavities, which are essential for the development of biosensors. The hydrophilic PEG linker contributes to the stability and performance of these biosensors in aqueous environments.
Used in Surfactant Synthesis:
In the chemical industry, Triethylene glycol monobenzyl ether is utilized in the synthesis of novel ethoxylated inositol surfactants. These surfactants have various applications, including detergents, emulsifiers, and stabilizers in the formulation of personal care products, pharmaceuticals, and other industrial products. The presence of the PEG linker and benzyl protecting group in Triethylene glycol monobenzyl ether plays a crucial role in the properties and performance of the resulting surfactants.

Check Digit Verification of cas no

The CAS Registry Mumber 55489-58-2 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 5,5,4,8 and 9 respectively; the second part has 2 digits, 5 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 55489-58:
(7*5)+(6*5)+(5*4)+(4*8)+(3*9)+(2*5)+(1*8)=162
162 % 10 = 2
So 55489-58-2 is a valid CAS Registry Number.
InChI:InChI=1/C13H20O4/c14-6-7-15-8-9-16-10-11-17-12-13-4-2-1-3-5-13/h1-5,14H,6-12H2

55489-58-2SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 12, 2017

Revision Date: Aug 12, 2017

1.Identification

1.1 GHS Product identifier

Product name Triethylene Glycol Monobenzyl Ether

1.2 Other means of identification

Product number -
Other names 2-[2-(2-phenylmethoxyethoxy)ethoxy]ethanol

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:55489-58-2 SDS

55489-58-2Relevant academic research and scientific papers

Synthesis of β-damascone from 2,6-dimethylcyclohexanone

Chaumont-Olive, Pauline,Plevová, Kristína,Collado Pérez, Ana María,Sánchez-Quesada, Jorge,?ebesta, Radovan,Cossy, Janine

supporting information, p. 140 - 150 (2022/02/10)

The synthesis of β-damascone can be achieved from 2,6-dimethylcyclohexanone using a Rupe rearrangement or a Barton vinyl iodation as the key steps.

One-Component Multifunctional Sequence-Defined Ionizable Amphiphilic Janus Dendrimer Delivery Systems for mRNA

Atochina-Vasserman, Elena N.,Billingsley, Margaret M.,Huang, Ning,Kim, Kyunghee,Liu, Matthew,Maurya, Devendra S.,Mitchell, Michael J.,Ni, Houping,Ona, Nathan,Percec, Virgil,Pochan, Darrin J.,Shahnawaz, Hamna,Weissman, Drew,Xiao, Qi,Zhang, Dapeng

supporting information, p. 12315 - 12327 (2021/08/20)

Efficient viral or nonviral delivery of nucleic acids is the key step of genetic nanomedicine. Both viral and synthetic vectors have been successfully employed for genetic delivery with recent examples being DNA, adenoviral, and mRNA-based Covid-19 vaccines. Viral vectors can be target specific and very efficient but can also mediate severe immune response, cell toxicity, and mutations. Four-component lipid nanoparticles (LNPs) containing ionizable lipids, phospholipids, cholesterol for mechanical properties, and PEG-conjugated lipid for stability represent the current leading nonviral vectors for mRNA. However, the segregation of the neutral ionizable lipid as droplets in the core of the LNP, the "PEG dilemma", and the stability at only very low temperatures limit their efficiency. Here, we report the development of a one-component multifunctional ionizable amphiphilic Janus dendrimer (IAJD) delivery system for mRNA that exhibits high activity at a low concentration of ionizable amines organized in a sequence-defined arrangement. Six libraries containing 54 sequence-defined IAJDs were synthesized by an accelerated modular-orthogonal methodology and coassembled with mRNA into dendrimersome nanoparticles (DNPs) by a simple injection method rather than by the complex microfluidic technology often used for LNPs. Forty four (81%) showed activity in vitro and 31 (57%) in vivo. Some, exhibiting organ specificity, are stable at 5 °C and demonstrated higher transfection efficiency than positive control experiments in vitro and in vivo. Aside from practical applications, this proof of concept will help elucidate the mechanisms of packaging and release of mRNA from DNPs as a function of ionizable amine concentration, their sequence, and constitutional isomerism of IAJDs.

INDAZOLE BASED COMPOUNDS AND ASSOCIATED METHODS OF USE

-

Paragraph 00228, (2021/10/02)

Bifunctional compounds, which find utility as modulators of leucine-rich repeat kinase 2 (LRRK2), are described herein. In particular, the hetero-bifunctional compounds of the present disclosure contain on one end a moiety that binds to the cereblon E3 ubiquitin ligase and on the other end a moiety which binds LRRK2, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The hetero-bifunctional compounds of the present disclosure exhibit a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aberrant regulation of the target protein are treated or prevented with compounds and compositions of the present disclosure.

TRICYCLIC CRBN LIGANDS AND USES THEREOF

-

Paragraph 0696; 0710; 0711, (2020/01/24)

The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of CRBN, and the treatment of CRBN-mediated disorders.

Design of nanosystems for the delivery of quorum sensing inhibitors: A preliminary study

Bortolotti, Daria,Cortesi, Rita,Esposito, Elisabetta,Hallan, Supandeep Singh,Marchetti, Paolo,Mariani, Paolo,Rizzo, Roberta,Sguizzato, Maddalena,Trapella, Claudio

, (2021/06/14)

Biofilm production is regulated by the Quorum Sensing system. Nowadays, Quorum Sensing represents an appealing target to design new compounds to increase antibiotics effects and avoid development of antibiotics multiresistance. In this research the use of liposomes to target two novel synthetic biofilm inhibitors is presented, focusing on a preformulation study to select a liposome composition for in vitro test. Five different liposome (LP) formulations, composed of phosphatidyl choline, cholesterol and charged surfactant (2:1:1, molar ratio) have been prepared by direct hydration and extrusion. As charged surfactants dicetyl phosphate didecyldimethylammonium chloride, di isobutyl phenoxy ethyl dimethyl benzyl ammonium chloride and stearylamine (SA) and have been used. Liposome charge, size and morphology were investigated by zeta potential, photon correlation spectroscopy, small angle x-ray spectroscopy and electron microscopy. LP-SA was selected for the loading of biofilm inhibitors and subjected to high performance liquid chromatography for entrapment capacity evaluation. LP-SA loaded inhibitors showed a higher diameter (223.6 nm) as compared to unloaded ones (205.7 nm) and a dose-dependent anti-biofilm effect mainly after 48 h of treatment, while free biofilm inhibitors loose activity. In conclusion, our data supported the use of liposomes as a strategy to enhance biofilm inhibitors effect.

Antibody drug conjugate, intermediate, preparation method, pharmaceutical composition and uses thereof

-

Page/Page column 149; 151, (2019/11/11)

Disclosed are an antibody drug conjugate IB, which uses ether linkages for connection, and improves the water solubility, stability and cytotoxicity in vivo and in intro, and an intermediate, a pharmaceutical composition, and uses of the antibody drug conjugate. The antibody drug conjugate has simple synthetic steps and a high yield.

IRAK DEGRADERS AND USES THEREOF

-

Paragraph 2026; 2027, (2019/07/10)

The present invention provides compounds, compositions thereof, and methods of using the same.

Benzoate Surfactants for Enhancing the Activity of Lipoprotein Lipase from Burkholderia Species in Organic Solvent

Oh, Yeonock

, p. 1093 - 1097 (2019/11/05)

Two benzoate surfactants were synthesized and examined as the additives for enhancing the activity of a lipoprotein lipase from Burkholderia species (BSLPL) in organic solvent. It was found that the benzoate surfactants enhanced the turnover number (kcat) by four orders of magnitude and the catalytic efficiency (kcat/Km) by three orders of magnitude. These results strongly suggest that the favorable interaction between the aromatic rings of surfactant tails and the hydrophobic residues around the active site of enzyme may help BSLPL maintain highly active open conformation in organic solvent.

TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE

-

Paragraph 1364, (2018/05/24)

The present disclosure relates to bifunctional compounds, which find utility as modulators of tau protein. In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a VHL or cereblon ligand which binds to the E3 ubiquitin ligase and on the other end a moiety which binds tau protein, such that tau protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of tau. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of tau protein. Diseases or disorders that result from aggregation or accumulation of tau protein are treated or prevented with compounds and compositions of the present disclosure.

Design, Synthesis, and Characterization of Brequinar Conjugates as Probes to Study DHODH Inhibition

Madak, Joseph T.,Cuthbertson, Christine R.,Chen, Wenmin,Showalter, Hollis D.,Neamati, Nouri

supporting information, p. 13875 - 13878 (2017/09/18)

Brequinar, a potent dihydroorotate dehydrogenase (DHODH) inhibitor, has been evaluated in multiple clinical trials as a potential treatment for cancer. To further understand brequinar-based DHODH inhibition and DHODH′s therapeutic relevance in cancer, we

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 55489-58-2